Thursday, October 23, 2025 10/23/2025

Gene Transcription in SLE

Award Number: R01AI049954
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2002
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Gene Transcription in SLE - The multitude of mechanisms that lead to general break of tolerance and organ pathology in patients with systemic lupus erythematosus (SLE) have challenged both basic immunologists and translational researchers. Our studies in people and mice with SLE have documented molecular mechanisms that account for the opposite production of interleukin 2 and interleukin 17, both of which are being exploited in clinical trials to treat people with SLE. We found that the transcription factor cAMP response element modulator, which accounts for the opposite transcription of the genes encoding for these two cytokines, controls also the expression of ADAM9, a disintegrin metalloproteinase. Early information indicates that ADAM9, a new comer in the field of autoimmunity, controls peripheral autoimmunity and organ inflammation. ADAM9 is expressed at increased levels in peripheral blood lymphocytes, lymphocytes entering tissues and tissue resident cells. We have built the hypothesis that ADAM9 controls systemic autoimmunity and organ damage through distinct molecular mechanisms. Using human cells and tissues and a series of newly constructed mice and novel technology to alter gene expression by delivering gRNA in a cell-targeted manner, we will establish that ADMA9 controls autoimmunity in SLE, that tissue hypoxia further promotes the expression of ADAM9 by cells entering tissues and its expression by tissue resident cells and how ADAM9 is involved in the aberrant tissue growth factor beta cell signaling in SLE T cells. Through this work metaloproteinases are introduced in the field of autoimmunity for the first time. The value of the work is based on the parallel use of human cells and tissues, novel engineered mice and cutting-edge approaches to alter the expression of molecules involved in the pathogenesis of SLE in a highly precise manner.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $597,513 )
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	24	5/22/2025	NON-COMPETING CONTINUATION	$597,513
														Subtotal = $597,513

Issue Date FY: 2024 ( Subtotal = $915,336 )
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	23	6/4/2024	NON-COMPETING CONTINUATION	$597,513
2024	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	22	3/19/2024	COMPETING CONTINUATION	$317,823
														Subtotal = $915,336

Issue Date FY: 2023 ( Subtotal = $597,513 )
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	22	6/13/2023	COMPETING CONTINUATION	$597,513
														Subtotal = $597,513

Issue Date FY: 2012 ( Subtotal = $416,543 )
2012	2012	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	11	1/27/2012	NON-COMPETING CONTINUATION	$416,543
														Subtotal = $416,543

Issue Date FY: 2011 ( Subtotal = $416,543 )
2011	2011	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	10	2/28/2011	NON-COMPETING CONTINUATION	$0
2011	2011	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	10	12/17/2010	NON-COMPETING CONTINUATION	$378,675
2011	2011	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	002	10	6/7/2011	NON-COMPETING CONTINUATION	$37,868
														Subtotal = $416,543

Issue Date FY: 2010 ( Subtotal = $420,750 )
2010	2010	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	9	12/31/2009	NON-COMPETING CONTINUATION	$382,500
2010	2010	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	9	6/4/2010	NON-COMPETING CONTINUATION	$38,250
														Subtotal = $420,750

Issue Date FY: 2009 ( Subtotal = $425,000 )
2009	2009	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	8	12/18/2008	NON-COMPETING CONTINUATION	$382,500
2009	2009	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	8	6/30/2009	NON-COMPETING CONTINUATION	$42,500
														Subtotal = $425,000

Issue Date FY: 2008 ( Subtotal = $425,000 )
2008	2008	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	7	12/19/2007	COMPETING CONTINUATION	$425,000
														Subtotal = $425,000

Issue Date FY: 2006 ( Subtotal = $253,256 )
2006	2006	HENRY M JACKSON FDN FOR ADVANCEMENT OF MILITARY MED	1401 ROCKVILLE PIKE, STE 600	ROCKVILLE	MD	20852	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	5	3/30/2006	NON-COMPETING CONTINUATION	$253,256
														Subtotal = $253,256

Issue Date FY: 2005 ( Subtotal = $259,350 )
2005	2005	HENRY M JACKSON FDN FOR ADVANCEMENT OF MILITARY MED	1401 ROCKVILLE PIKE, STE 600	ROCKVILLE	MD	20852	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	4	3/22/2005	NON-COMPETING CONTINUATION	$259,350
														Subtotal = $259,350

Issue Date FY: 2004 ( Subtotal = $259,350 )
2004	2004	HENRY M JACKSON FDN FOR ADVANCEMENT OF MILITARY MED	1401 ROCKVILLE PIKE, STE 600	ROCKVILLE	MD	20852	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	3	3/24/2004	NON-COMPETING CONTINUATION	$259,350
														Subtotal = $259,350

Issue Date FY: 2003 ( Subtotal = $259,350 )
2003	2003	HENRY M JACKSON FDN FOR ADVANCEMENT OF MILITARY MED	1401 ROCKVILLE PIKE, STE 600	ROCKVILLE	MD	20852	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2		NON-COMPETING CONTINUATION	$259,350
														Subtotal = $259,350

Issue Date FY: 2002 ( Subtotal = $259,350 )
2002	2002	HENRY M JACKSON FDN FOR ADVANCEMENT OF MILITARY MED	1401 ROCKVILLE PIKE, STE 600	ROCKVILLE	MD	20852	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	4/10/2002	NEW	$259,350
														Subtotal = $259,350

Grand Total All Awards = $5,504,854

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Gene Transcription in SLE

Award Number: R01AI049954

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2002

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer